JP2005512998A - 抗マラリア治療剤に対する新規の使用 - Google Patents

抗マラリア治療剤に対する新規の使用 Download PDF

Info

Publication number
JP2005512998A
JP2005512998A JP2003541837A JP2003541837A JP2005512998A JP 2005512998 A JP2005512998 A JP 2005512998A JP 2003541837 A JP2003541837 A JP 2003541837A JP 2003541837 A JP2003541837 A JP 2003541837A JP 2005512998 A JP2005512998 A JP 2005512998A
Authority
JP
Japan
Prior art keywords
hydrogen
antimalarial
infection
substituted
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005512998A5 (enExample
Inventor
ローレン チャロウス、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005512998A publication Critical patent/JP2005512998A/ja
Publication of JP2005512998A5 publication Critical patent/JP2005512998A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003541837A 2001-11-09 2002-11-12 抗マラリア治療剤に対する新規の使用 Pending JP2005512998A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34587201P 2001-11-09 2001-11-09
PCT/US2002/036309 WO2003039546A1 (en) 2001-11-09 2002-11-12 New uses for anti-malarial therapeutic agents

Publications (2)

Publication Number Publication Date
JP2005512998A true JP2005512998A (ja) 2005-05-12
JP2005512998A5 JP2005512998A5 (enExample) 2006-02-23

Family

ID=23356861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541837A Pending JP2005512998A (ja) 2001-11-09 2002-11-12 抗マラリア治療剤に対する新規の使用

Country Status (9)

Country Link
US (1) US20040167162A1 (enExample)
EP (1) EP1450803A4 (enExample)
JP (1) JP2005512998A (enExample)
CN (1) CN1289086C (enExample)
AU (1) AU2002363443B2 (enExample)
CA (1) CA2466338C (enExample)
IL (1) IL161821A0 (enExample)
MX (1) MXPA04004393A (enExample)
WO (1) WO2003039546A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527478A (ja) * 2006-02-16 2009-07-30 ザ マクレーン ホスピタル コーポレーション パーキンソン病の治療のための方法と組成物
JP2019527207A (ja) * 2016-06-28 2019-09-26 アシスタンス ピュブリーク−オピト ド パリＡｓｓｉｓｔａｎｃｅ Ｐｕｂｌｉｑｕｅ−Ｈｏｐｉｔａｕｘ Ｄｅ Ｐａｒｉｓ ガンマヘルペスウイルスに関連した障害の予防および／または処置での使用のためのヒカントン誘導体およびプリマキン誘導体
JP2023512093A (ja) * 2020-02-03 2023-03-23 アカデミー オブ ミリタリー メディカル サイエンシズ コロナウイルス感染の治療における４－アミノキノリン化合物の使用
JP2023523035A (ja) * 2020-04-21 2023-06-01 コーエン ノーム キニーネ及び先天性免疫応答を生じさせるためのその使用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
BR0318214A (pt) * 2003-03-27 2006-03-21 Council Scient Ind Res análogos de 8-aminoquinolina substituìda no anel, composição anti-malárica, processo para a preparação de análogos de 8-aminoquinolina substituìda no anel, e, uso de análogos de 8-aminoquinolina substituìda no anel
US20070134596A1 (en) * 2005-12-08 2007-06-14 Adrian Lungu Photosensitive printing element having nanoparticles and method for preparing the printing element
KR101067443B1 (ko) * 2009-06-23 2011-09-27 여오영 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
CN103027915A (zh) * 2011-09-29 2013-04-10 中国医学科学院基础医学研究所 氯喹治疗和氯丙嗪预防肺感染和损伤的用途
CN103705516B (zh) * 2013-12-11 2016-01-06 武汉威立得生物医药有限公司 氯喔星在制备治疗或预防流感病毒感染的药物中的应用
KR101828553B1 (ko) * 2016-04-15 2018-02-13 한국화학연구원 신규한 벤조싸이오펜 유도체, 이의 약학적으로 허용 가능한 염 또는 이의 광학 이성질체, 이의 제조방법 및 이를 유효성분으로 함유하는 바이러스성 질환의 예방 또는 치료용 약학적 조성물
US20210244705A1 (en) * 2020-02-07 2021-08-12 Centre For Digestive Diseases Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN114908061B (zh) * 2020-02-16 2023-10-27 北京化工大学 穿山甲冠状病毒xCoV及其应用
US11007187B1 (en) * 2020-03-25 2021-05-18 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
US11638722B2 (en) 2020-03-25 2023-05-02 Therapeutica Borealis Oy C/O Avance Attorneys Ltd. Medicine for Covid-19 and treatment
WO2021191496A1 (en) * 2020-03-25 2021-09-30 Therapeutica Borealis Oy Medicine for covid-19 and treatment
US11278602B2 (en) 2020-03-25 2022-03-22 Therapeutica Borealis Oy Medicine for Covid-19 and treatment
WO2021204717A1 (en) * 2020-04-06 2021-10-14 Oxandia Ltd Aminoquinolines for treating coronavirus infections
EP3892275A1 (en) * 2020-04-08 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hcq or its metabolites for the treatment of lung infections
US20230123388A1 (en) * 2020-04-14 2023-04-20 Glanis Pharmaceuticals, Inc. Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
AU2021261049A1 (en) * 2020-04-24 2022-11-10 Topelia Aust Limited Products of manufacture and methods for treating, ameliorating or preventing microbial infections
WO2021219244A1 (en) * 2020-04-27 2021-11-04 Immunologik Gmbh 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections
CN115515935B (zh) * 2020-04-30 2025-01-07 中美华世通生物医药科技(武汉)股份有限公司 冠状病毒感染的治疗或预防
IL301183A (en) * 2020-09-14 2023-05-01 Philip Morris Products Sa Pharmaceutical composition comprising hydroxychloroquine and uses thereof
DE102021000717A1 (de) * 2021-02-12 2022-08-18 Forschungszentrum Jülich GmbH Quinacrin als lnhibitor viraler Cysteinproteasen und/oder Serinproteasen
US20240391876A1 (en) * 2021-08-19 2024-11-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Quinacrine and derivatives thereof for treatment of viral infections
CN115869311A (zh) * 2022-12-30 2023-03-31 湖北工业大学 MefloquineHydrochloride在制备抗腺病毒ADV7药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
US4496549A (en) * 1983-01-17 1985-01-29 American Cyanamid Company Treatment of malaria with antibiotics
US5153202A (en) * 1988-06-30 1992-10-06 Davis Michael H Method of inhibiting the activity of human immuno deficiency virus (HIV) in vivo
US5376359A (en) * 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US5827681A (en) * 1996-12-20 1998-10-27 University Technology Corporation Rapid detection and drug sensitivity of malaria
WO2000066107A2 (en) * 1999-04-30 2000-11-09 Apt Pharmaceuticals, L.L.C. Antimalarian agents for the treatment of asthma

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009527478A (ja) * 2006-02-16 2009-07-30 ザ マクレーン ホスピタル コーポレーション パーキンソン病の治療のための方法と組成物
JP2019527207A (ja) * 2016-06-28 2019-09-26 アシスタンス ピュブリーク−オピト ド パリＡｓｓｉｓｔａｎｃｅ Ｐｕｂｌｉｑｕｅ−Ｈｏｐｉｔａｕｘ Ｄｅ Ｐａｒｉｓ ガンマヘルペスウイルスに関連した障害の予防および／または処置での使用のためのヒカントン誘導体およびプリマキン誘導体
JP2023512093A (ja) * 2020-02-03 2023-03-23 アカデミー オブ ミリタリー メディカル サイエンシズ コロナウイルス感染の治療における４－アミノキノリン化合物の使用
JP2023523035A (ja) * 2020-04-21 2023-06-01 コーエン ノーム キニーネ及び先天性免疫応答を生じさせるためのその使用

Also Published As

Publication number Publication date
US20040167162A1 (en) 2004-08-26
IL161821A0 (en) 2005-11-20
CA2466338A1 (en) 2003-05-15
HK1075619A1 (en) 2005-12-23
EP1450803A1 (en) 2004-09-01
AU2002363443B2 (en) 2006-02-16
CN1289086C (zh) 2006-12-13
CN1612735A (zh) 2005-05-04
MXPA04004393A (es) 2005-09-12
CA2466338C (en) 2010-01-12
EP1450803A4 (en) 2008-09-03
WO2003039546A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
JP2005512998A (ja) 抗マラリア治療剤に対する新規の使用
AU2002363443A1 (en) New uses for anti-malarial therapeutic agents
US11975005B2 (en) Treatment of respiratory diseases
KR101805958B1 (ko) 포스포디에스테라제 억제제를 포함하는 건조 분말 제제
US6572858B1 (en) Uses for anti-malarial therapeutic agents
US20070065366A1 (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
JP2014525471A (ja) 咳および咳発作の治療
WO2021229514A1 (en) Pharmaceutical ivermectin compositions
KR102462058B1 (ko) 제제의 안정성을 증가시키기 위해 분무 건조에 의해 수득된 1종 이상의 건조 분말을 포함하는 조성물
KR20070042917A (ko) 소아 천식의 치료
CN105338967B (zh) 包含布地奈德和福莫特罗的药物组合物
WO2021204717A1 (en) Aminoquinolines for treating coronavirus infections
AU2021200396B2 (en) Pharmaceutical composition containing budesonide and formoterol
WO2022007743A1 (zh) 粘膜给药剂型和其应用
HK1075619B (en) New uses for anti-malarial therapeutic agents
KR20050034760A (ko) 선택적 포스포디에스테라제-4 억제제에 의한 비알레르기성비염의 치료방법

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20051129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090106